Aripiprazole use in an individual with intellectual disability and schizoaffective disorder

Gerard Gallucci, Lawrence Mernaugh, Donald Dyson

Research output: Contribution to journalArticle


The treatment of individuals with intellectual/developmental disabilities and schizophrenia or related disorders represents a challenge for clinicians. Individuals with cognitive impairment may be especially vulnerable to the adverse effects of conventional and atypical antipsychotic drugs. We report on the successful treatment of an individual with schizoaffective disorder and intellectual disability with aripiprazole, a novel antipsychotic agent with a favorable side effect profile.

Original languageEnglish (US)
Pages (from-to)53-56
Number of pages4
JournalMental Health Aspects of Developmental Disabilities
Issue number2
Publication statusPublished - Apr 2004



  • Aripiprazole
  • Atypical antipsychotics
  • Diabetes mellitus
  • Intellectual/developmental disability
  • Mental retardation
  • Psychiatric disorder
  • Schizoaffective disorder
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this